Athira Pharma, Inc. — Director's Dealing 2022

Mar 21, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2022-03-18

Reporting Person: Panzara Michael A. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-18	Stock Option (Right to Buy)	$10.62	A	27742	Acquired	2032-03-17	Common Stock (27742)	Direct

Footnotes

F1: One thirty-sixth of the shares subject to the option will vest on April 18, 2022 and one thirty-sixth of the shares subject to the option will vest each month thereafter.